Mixed trend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Sep 23 · below the Ichimoku cloud · RSI 44 · MACD below its signal
None of the 29 investors followed here reported a position in FOCL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a FOCL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Willsey LanceDirector | Purchase at price 4.75 per share. | 50K | $237.50K |
| Aug 13, 2026 | Levine Joshua HDirector | Purchase at price 4.75 per share. | 10K | $47.50K |
| Aug 13, 2026 | Annen StevenOfficer | Purchase at price 4.75 per share. | 5K | $23.75K |
| Aug 13, 2026 | Rhodes RyanChief Executive Officer | Purchase at price 4.75 per share. | 21K | $99.75K |
| Aug 13, 2026 | Horn David R.Director | Purchase at price 4.75 per share. | 10K | $47.50K |
| Aug 13, 2026 | Shah SanketGeneral Counsel | Purchase at price 4.75 per share. | 5K | $23.75K |
| Aug 13, 2026 | Schulz FranDirector | Purchase at price 4.75 per share. | 10K | $47.50K |
| Aug 13, 2026 | Mobeck Kenneth S.Chief Financial Officer | Purchase at price 4.75 per share. | 5K | $23.75K |
| May 11, 2026 | Annen StevenOfficer | Stock Award(Grant) at price 0.00 per share. | 90K | — |
| May 11, 2026 | Rhodes RyanChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 304.5K | — |
| May 11, 2026 | Shah SanketGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 67.5K | — |
| May 11, 2026 | Mobeck Kenneth S.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 120K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 27.7 | 4.0 | -14.9 | -10.8 | 30.1 | 19.9 | 18.1 | -30.2 | 4.7 | -6.0 | +27.7% | ||
| 2025 | 10.4 | 4.9 | -23.4 | 8.2 | -16.0 | -7.3 | -15.2 | 61.4 | 1.3 | -6.6 | 12.1 | 37.1 | +48.9% |
| 2024 | 25.9 | -5.0 | 16.3 | -4.2 | -15.5 | -8.6 | -10.1 | -26.0 | -29.6 | 13.7 | -15.9 | -9.4 | −58.1% |
| 2023 | 3.2 | 7.0 | -5.9 | -2.7 | -7.7 | -7.2 | -1.1 | -11.7 | -12.8 | -1.3 | -24.7 | 1.1 | −50.5% |
| 2022 | 16.9 | 3.3 | 0.3 | -2.8 | 4.5 | -7.7 | 8.5 | 14.8 | -2.6 | 14.9 | 19.4 | -5.8 | +78.0% |
| 2021 | 49.1 | 18.0 | -7.7 | -18.1 | -1.9 | 5.0 | -10.9 | -4.7 | 6.0 | -4.7 | -6.1 | 4.9 | +15.9% |
| 2020 | -14.2 | 0.8 | -40.7 | 0.4 | 18.4 | -8.5 | 24.3 | 30.9 | 14.4 | -7.8 | -6.1 | 29.9 | +16.7% |
| 2019 | 43.8 | 5.6 | 6.8 | 65.3 | -40.9 | -7.8 | 19.3 | -1.6 | 41.6 | 12.0 | 0.6 | -12.5 | +139.5% |
| 2018 | -10.5 | -6.2 | -3.7 | -3.0 | -0.4 | 35.3 | 5.0 | -5.3 | 2.3 | -15.6 | 2.7 | -30.7 | −35.5% |
| 2017 | -2.1 | -12.1 | -1.8 | -4.7 | 0.4 | 24.5 | -4.5 | -6.3 | 1.0 | 3.7 | -2.9 | -4.3 | −12.5% |
| 2016 | -14.3 | 14.7 | -1.0 | -14.9 | 2.0 | -5.2 | -6.0 | -6.1 | -0.7 | -9.7 | 15.6 | 8.3 | −20.6% |
| 2015 | 30.5 | 25.0 | -4.5 | -16.3 | 10.2 | -3.0 | 15.1 | -2.4 | 53.2 | -14.8 | 14.1 | -23.9 | +77.3% |
| 2014 | 5.8 | 6.4 | -13.9 | 11.5 | 0.3 | 55.6 | -61.4 | -18.8 | -16.0 | 27.5 | 53.9 | -9.3 | −21.0% |
| 2013 | 26.5 | 58.1 | 2.2 | -8.9 | 1.6 | -29.5 | -2.2 | -6.8 | 2.0 | 3.6 | 8.0 | 4.2 | +44.6% |
| 2012 | 47.9 | -10.8 | -14.8 | 12.6 | -14.5 | 6.0 | -11.3 | 6.4 | -6.6 | 4.1 | -7.9 | 24.4 | +20.7% |
| 2011 | -32.4 | -8.7 | 0.3 | 16.9 | -7.6 | -13.0 | 6.1 | -36.5 | -20.8 | 8.6 | -12.6 | 1.8 | −70.0% |
| 2010 | -14.5 | 0.0 | 34.5 | 7.6 | -27.4 | -5.7 | -11.2 | 8.7 | 7.1 | -0.8 | 71.5 | 37.6 | +105.1% |
| 2009 | -0.7 | 18.9 | -11.8 | -28.0 | 57.4 | -11.8 | -2.7 | 171.2 | 1.0 | -20.5 | -0.3 | -13.2 | +91.0% |
| 2008 | -24.8 | 13.6 | -13.9 | -2.5 | 3.2 | -14.6 | -1.0 | -9.3 | -28.3 | -11.8 | -4.7 | -12.2 | −70.0% |
| 2007 | 33.4 | -5.4 | -12.7 | -1.1 | 2.3 | 2.3 | -0.9 | -4.4 | -9.6 | -0.7 | -18.4 | 3.2 | −18.2% |
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
Buy / hold / sell counts